Lee's Pharma Gains China Rights to Liver Cancer Drug from Tragara
November 16, 2015 at 05:59 AM EST
Lee's Pharma has in-licensed Greater China and Southeast Asia rights to a potential liver cancer treatment from Tragara Pharma of San Diego. The drug is Tragara's oral multi-kinase inhibitor, TG02, which is currently in Phase Ib trials in the US. Lee's participated in Tragara's $13 million capital raise and made an upfront payment. Tragara is eligible for milestones and tiered royalties on future sales, while Lee’s will be responsible for all development and commercialization costs. More details.... Stock Symbol: (HK: 950) Share this with colleagues: // //